{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T13:25:27Z","timestamp":1794144327225,"version":"4.8.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100011595","name":"Swiss Foundation for Alcohol Research","doi-asserted-by":"publisher","award":["343"],"award-info":[{"award-number":["343"]}],"id":[{"id":"10.13039\/501100011595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["10001356"],"award-info":[{"award-number":["10001356"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Contemporary clinical trials of PAT for AUD were identified systematically from PubMed, PsycINFO, and Scopus by two independent reviewers. Random-effects meta-analyses were conducted to synthesize within-group pre\u2013post changes and between-group differences from randomized controlled trials (RCTs). Primary outcomes included continuous drinking measures and abstinence rates; secondary outcomes included adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Six trials (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009202) met inclusion criteria (3 RCTs). PAT produced significant within-group reductions across all drinking outcomes that were sustained at mid- to long-term follow-up (4\u201328\u2009weeks). Compared to controls, psilocybin demonstrated moderate short-term advantages for drinks per day (standardized mean differences (SMD)\u2009=\u20090.48;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004), percent drinking days (SMD\u2009=\u20090.50;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.009), and percent heavy drinking days (SMD\u2009=\u20090.39;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.020). At mid- to long-term follow-up, only percent drinking days remained significantly superior (SMD\u2009=\u20090.41;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.032). Psilocybin-treated patients had significantly higher odds of maintaining abstinence compared to controls (OR\u2009=\u20092.78;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.029). AEs were predominantly mild and transient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Current evidence for PAT in AUD is mixed but suggests preliminary signals of efficacy for reducing alcohol consumption and increasing the odds of maintaining long-term abstinence. The intervention was well-tolerated with a favorable safety profile, supporting its potential as a novel treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261490221","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:11:53Z","timestamp":1791526313000},"page":"1771-1783","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1111-5902","authenticated-orcid":false,"given":"Gianluca A.","family":"Florineth","sequence":"first","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"},{"name":"Graduate School for Health Sciences, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7316-4969","authenticated-orcid":false,"given":"Anna L.","family":"Boeker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (UPK), University of Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-8564","authenticated-orcid":false,"given":"Tobias","family":"Bracht","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"},{"name":"Competence Center for Interventional Psychiatry and Augmented Psychotherapy, University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wopfner","sequence":"additional","affiliation":[{"name":"S\u00fcdhang Clinic, Kirchlindach, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Denier","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Adorjan","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-6610","authenticated-orcid":false,"given":"Felix","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (UPK), University of Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-7771","authenticated-orcid":false,"given":"Leila M.","family":"Soravia","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"},{"name":"Competence Center for Interventional Psychiatry and Augmented Psychotherapy, University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"crossref","unstructured":"An J Wang Q Bai Z et al. (2025) Global burden and trend of substance use disorders self-harm and interpersonal violence from 1990 to 2021 with projection to 2040. BMC Public Health 25(1): 1632. https:\/\/doi.org\/10.1186\/s12889-025-22814-0","DOI":"10.1186\/s12889-025-22814-0"},{"key":"e_1_3_5_3_1","doi-asserted-by":"crossref","unstructured":"Bahji A Bach P Danilewitz M et al. (2022) Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis. Journal of Addiction Medicine 16(6): 630. https:\/\/doi.org\/10.1097\/ADM.0000000000000992","DOI":"10.1097\/ADM.0000000000000992"},{"key":"e_1_3_5_4_1","doi-asserted-by":"crossref","unstructured":"Balduzzi S R\u00fccker G Schwarzer G (2019) How to perform a meta-analysis with R: A practical tutorial. Evidence-Based Mental Health 22(4): 153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_3_5_5_1","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP Forcehimes AA Pommy JA et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29(3): 289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","DOI":"10.1177\/0269881114565144"},{"key":"e_1_3_5_6_1","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP Ross S Bhatt S et al. (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry 79(10): 953\u2013962. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_3_5_7_1","doi-asserted-by":"crossref","unstructured":"Burke BL Arkowitz H Menchola M (2003) The efficacy of motivational interviewing: A meta-analysis of controlled clinical trials. Journal of Consulting and Clinical Psychology 71(5): 843\u2013861. https:\/\/doi.org\/10.1037\/0022-006X.71.5.843","DOI":"10.1037\/0022-006X.71.5.843"},{"key":"e_1_3_5_8_1","doi-asserted-by":"crossref","unstructured":"Davis AK Barrett FS May DG et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78(5): 481. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_5_9_1","doi-asserted-by":"crossref","unstructured":"Donato S Ray LA (2023) Neurobiology and the treatment of alcohol use disorder: A review of the evidence base. Substance Abuse and Rehabilitation 14: 157\u2013166. https:\/\/doi.org\/10.2147\/SAR.S409943","DOI":"10.2147\/SAR.S409943"},{"key":"e_1_3_5_10_1","doi-asserted-by":"crossref","unstructured":"Doss MK Pova\u017ean M Rosenberg MD et al. (2021) Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry 11(1): 574. https:\/\/doi.org\/10.1038\/s41398-021-01706-y","DOI":"10.1038\/s41398-021-01706-y"},{"key":"e_1_3_5_11_1","doi-asserted-by":"crossref","unstructured":"Geyer MA (2024) A brief historical overview of psychedelic research. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 9(5): 464\u2013471. https:\/\/doi.org\/10.1016\/j.bpsc.2023.11.003","DOI":"10.1016\/j.bpsc.2023.11.003"},{"key":"e_1_3_5_12_1","doi-asserted-by":"crossref","unstructured":"Ghosh A Morgan N Calvey T et al. (2024) Effectiveness of psychosocial interventions for alcohol use disorder: A systematic review and meta-analysis update. The American Journal of Drug and Alcohol Abuse 50(4): 442\u2013454. https:\/\/doi.org\/10.1080\/00952990.2024.2350056","DOI":"10.1080\/00952990.2024.2350056"},{"key":"e_1_3_5_13_1","doi-asserted-by":"crossref","unstructured":"Grabski M McAndrew A Lawn W et al. (2022) Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. The American Journal of Psychiatry 179(2): 152\u2013162. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21030277","DOI":"10.1176\/appi.ajp.2021.21030277"},{"key":"e_1_3_5_14_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Johnson MW Carducci MA et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30(12): 1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_5_15_1","doi-asserted-by":"crossref","unstructured":"Hayes A Herlinger K Paterson L et al. (2020) The neurobiology of substance use and addiction: Evidence from neuroimaging and relevance to treatment. BJPsych Advances 26(6): 367\u2013378. https:\/\/doi.org\/10.1192\/bja.2020.68","DOI":"10.1192\/bja.2020.68"},{"key":"e_1_3_5_16_1","doi-asserted-by":"crossref","unstructured":"Heinzerling KG Sergi K Linton M et al. (2023) Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Frontiers in Psychiatry 14: 1215972. https:\/\/doi.org\/10.3389\/fpsyt.2023.1215972","DOI":"10.3389\/fpsyt.2023.1215972"},{"key":"e_1_3_5_17_1","doi-asserted-by":"crossref","unstructured":"Hieronymus F L\u00f3pez E Werin Sj\u00f6gren H et al. (2025) Control group outcomes in trials of psilocybin SSRIs or esketamine for depression: A meta-analysis. JAMA Network Open 8(7): e2524119. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.24119","DOI":"10.1001\/jamanetworkopen.2025.24119"},{"key":"e_1_3_5_18_1","doi-asserted-by":"crossref","unstructured":"Holze F Gasser P M\u00fcller F et al. (2023) Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized double-blind placebo-controlled phase II study. Biological Psychiatry 93(3): 215\u2013223. https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_3_5_19_1","doi-asserted-by":"crossref","unstructured":"Jensen ME Stenb\u00e6k DS Messell CD et al. (2025) Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics feasibility safety and efficacy in an open-label study. Journal of Psychopharmacology (Oxford England) 39(5): 463\u2013473. https:\/\/doi.org\/10.1177\/02698811251319457","DOI":"10.1177\/02698811251319457"},{"key":"e_1_3_5_20_1","doi-asserted-by":"crossref","unstructured":"Keighley EE Abo Hamza E Bedewy DA et al. (2025) A systematic review and meta-analysis investigating the efficacy of various psychedelic drugs for the treatment of substance use disorder. Healthcare 13(21): 2668. https:\/\/doi.org\/10.3390\/healthcare13212668","DOI":"10.3390\/healthcare13212668"},{"key":"e_1_3_5_21_1","doi-asserted-by":"crossref","unstructured":"Koob GF (2024) Alcohol use disorder treatment: Problems and solutions. Annual Review of Pharmacology and Toxicology 64: 255\u2013275. https:\/\/doi.org\/10.1146\/annurev-pharmtox-031323-115847","DOI":"10.1146\/annurev-pharmtox-031323-115847"},{"key":"e_1_3_5_22_1","doi-asserted-by":"crossref","unstructured":"Koob GF Volkow ND (2016) Neurobiology of addiction: A neurocircuitry analysis. The Lancet. Psychiatry 3(8): 760\u2013773. https:\/\/doi.org\/10.1016\/S2215-0366(16)00104-8","DOI":"10.1016\/S2215-0366(16)00104-8"},{"key":"e_1_3_5_23_1","doi-asserted-by":"crossref","unstructured":"Kotake K Hosokawa T Tanaka M et al. (2024) Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis. Addiction (Abingdon England) 119(5): 815\u2013832. https:\/\/doi.org\/10.1111\/add.16421","DOI":"10.1111\/add.16421"},{"key":"e_1_3_5_24_1","doi-asserted-by":"crossref","unstructured":"Kranzler HR Soyka M (2018) Diagnosis and pharmacotherapy of alcohol use disorder: A review. JAMA 320(8): 815\u2013824. https:\/\/doi.org\/10.1001\/jama.2018.11406","DOI":"10.1001\/jama.2018.11406"},{"key":"e_1_3_5_25_1","doi-asserted-by":"crossref","unstructured":"Krebs TS Johansen P-\u00d8 (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26(7): 994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253","DOI":"10.1177\/0269881112439253"},{"key":"e_1_3_5_26_1","doi-asserted-by":"crossref","unstructured":"Luquiens A Belahda D Graux C et al. (2025) Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. Epub ahead of print 24 July 2025. https:\/\/doi.org\/10.1111\/add.70152","DOI":"10.1111\/add.70152"},{"key":"e_1_3_5_27_1","doi-asserted-by":"crossref","unstructured":"Magill M Ray L Kiluk B et al. (2019) A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. Journal of Consulting and Clinical Psychology 87(12): 1093\u20131105. https:\/\/doi.org\/10.1037\/ccp0000447","DOI":"10.1037\/ccp0000447"},{"key":"e_1_3_5_28_1","doi-asserted-by":"crossref","unstructured":"Marsden J Kelleher M Dunbar F et al. (2025) 5-Methoxy-N N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label phase 2 proof-of-concept clinical trial. Addiction. Epub ahead of print 10 December 2025. https:\/\/doi.org\/10.1111\/add.70260","DOI":"10.1111\/add.70260"},{"key":"e_1_3_5_29_1","doi-asserted-by":"crossref","unstructured":"McCrone P Fisher H Knight C et al. (2023) Cost-effectiveness of psilocybin-assisted therapy for severe depression: Exploratory findings from a decision analytic model. Psychological Medicine 53(16): 7619\u20137626. https:\/\/doi.org\/10.1017\/S0033291723001411","DOI":"10.1017\/S0033291723001411"},{"key":"e_1_3_5_30_1","doi-asserted-by":"crossref","unstructured":"McPheeters M O\u2019Connor EA Riley S et al. (2023) Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA 330(17): 1653\u20131665. https:\/\/doi.org\/10.1001\/jama.2023.19761","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_3_5_31_1","doi-asserted-by":"crossref","unstructured":"Meshkat S Malik G Zeifman RJ et al. (2025) Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience and Biobehavioral Reviews 173: 106163. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106163","DOI":"10.1016\/j.neubiorev.2025.106163"},{"key":"e_1_3_5_32_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.001","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_5_33_1","doi-asserted-by":"crossref","unstructured":"Raison CL Sanacora G Woolley J et al. (2023) Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330(9): 843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_5_34_1","doi-asserted-by":"crossref","unstructured":"Rieser NM Bitar R Halm S et al. (2025) Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. EClinicalMedicine 82: 103149. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103149","DOI":"10.1016\/j.eclinm.2025.103149"},{"key":"e_1_3_5_35_1","doi-asserted-by":"crossref","unstructured":"Rucker JJH Iliff J Nutt DJ (2018) Psychiatry & the psychedelic drugs. Past present & future. Neuropharmacology 142: 200\u2013218. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"e_1_3_5_36_1","doi-asserted-by":"crossref","unstructured":"Sicignano D Hernandez AV Schiff B et al. (2024) The impact of psychedelics on patients with alcohol use disorder: A systematic review with meta-analysis. Current Medical Research and Opinion 40(2): 293\u2013302. https:\/\/doi.org\/10.1080\/03007995.2023.2296968","DOI":"10.1080\/03007995.2023.2296968"},{"key":"e_1_3_5_37_1","doi-asserted-by":"crossref","unstructured":"Sliedrecht W De Waart R Witkiewitz K et al. (2019) Alcohol use disorder relapse factors: A systematic review. Psychiatry Research 278: 97\u2013115. https:\/\/doi.org\/10.1016\/j.psychres.2019.05.038","DOI":"10.1016\/j.psychres.2019.05.038"},{"key":"e_1_3_5_38_1","doi-asserted-by":"crossref","unstructured":"Sterne JAC Hern\u00e1n MA Reeves BC et al. (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355: i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_5_39_1","doi-asserted-by":"crossref","unstructured":"Sterne JAC Savovi\u0107 J Page MJ et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_5_41_1","doi-asserted-by":"crossref","unstructured":"Williams ZJ Barnett H Szigeti B (2026) Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions: A systematic review and meta-analysis. JAMA Psychiatry 83(5): 461\u2013468. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4809","DOI":"10.1001\/jamapsychiatry.2025.4809"},{"key":"e_1_3_5_42_1","doi-asserted-by":"crossref","unstructured":"Wolff M Rutrecht H Mertens LJ et al. (2025) Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe\u2019s general change mechanisms. Psychological Review 132(6): 1467\u20131492. https:\/\/doi.org\/10.1037\/rev0000589","DOI":"10.1037\/rev0000589"},{"key":"e_1_3_5_43_1","doi-asserted-by":"crossref","unstructured":"Ziadi Y Park T (2026) Cost-effectiveness of psilocybin-assisted therapy versus standard of care for patients with treatment-resistant depression. Value in Health Regional Issues 56: 101605. https:\/\/doi.org\/10.1016\/j.vhri.2026.101605","DOI":"10.1016\/j.vhri.2026.101605"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261490221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261490221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261490221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T13:19:53Z","timestamp":1794143993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261490221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/02698811261490221"],"URL":"https:\/\/doi.org\/10.1177\/02698811261490221","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}